A powerful House committee is turning up the heat on the cannabis industry—this time over what companies are saying, not just what they’re selling.
In a newly approved spending bill report, lawmakers are urging federal regulators—especially the FDA—to crack down on cannabis product manufacturers that make unproven or misleading health claims.
The concern? A flood of products being marketed as treatments for serious conditions—without the science to back it up. Lawmakers say some companies are crossing the line by suggesting cannabis can treat diseases like cancer or other major illnesses, despite lacking FDA approval.
The committee is essentially telling regulators: start enforcing the rules already on the books. That means going after companies making “unlawful therapeutic claims” and protecting the integrity of the drug approval process, which requires rigorous testing for safety and effectiveness.
At the same time, lawmakers acknowledge the booming demand for hemp-derived and cannabis products—but say that growth needs guardrails. They’re pushing for clearer, science-based regulations to ensure consumer safety and restore confidence in the market.
The feds may not be shutting down cannabis—but they are signaling that wild health claims could be the next big crackdown target.
Dabbin-Dad Newsroom
